<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hemorrhagic transformation (HT) is an important complication of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> particularly in diabetic patients receiving thrombolytic treatment with tissue plasminogen activator (tPA), the only approved drug for the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> (AIS) </plain></SENT>
<SENT sid="1" pm="."><plain>The objective of the current study was to determine the effects of <z:hpo ids='HP_0011009'>acute</z:hpo> manipulation of potential targets for vascular protection (i.e., NFkB, <z:chebi fb="0" ids="25941">peroxynitrite</z:chebi>, and matrix metalloproteinases) on vascular injury and functional outcome in a diabetic model of <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">Ischemia</z:e> was induced by middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> in control and type 2 diabetic Goto-Kakizaki rats </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment groups received a single dose of <z:chebi fb="0" ids="25941">peroxynitrite</z:chebi> decomposition catalyst FeTPPs,a non-specific NFkB inhibitor <z:chebi fb="0" ids="3962">curcumin</z:chebi>, or a broad-spectrum matrix metalloproteinase (MMP) inhibitor <z:chebi fb="1" ids="50694">minocycline</z:chebi> at reperfusion </plain></SENT>
<SENT sid="4" pm="."><plain>Post-<z:hpo ids='HP_0001297'>stroke</z:hpo> <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, <z:hpo ids='HP_0000969'>edema</z:hpo>, <z:mp ids='MP_0001914'>hemorrhage</z:mp>, neurological deficits, and MMP-9 activity were evaluated </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:hpo ids='HP_0011009'>acute</z:hpo> treatments reduced MMP-9 and HT in diabetic groups </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, <z:hpo ids='HP_0011009'>acute</z:hpo> <z:chebi fb="0" ids="3962">curcumin</z:chebi> and <z:chebi fb="1" ids="50694">minocycline</z:chebi> therapy reduced <z:hpo ids='HP_0000969'>edema</z:hpo> in these animals </plain></SENT>
<SENT sid="7" pm="."><plain>Improved neurological function was observed in varying degrees with treatment as indicated by beam-walk performance, modified Bederson scores and grip strength; however, <z:mpath ids='MPATH_124'>infarct</z:mpath> size was similar to untreated diabetic animals </plain></SENT>
<SENT sid="8" pm="."><plain>In control animals, <z:hpo ids='HP_0000001'>all</z:hpo> treatments reduced MMP-9 activity yet <z:mp ids='MP_0001914'>bleeding</z:mp> was not improved </plain></SENT>
<SENT sid="9" pm="."><plain>Neuroprotection was only conferred by <z:chebi fb="0" ids="3962">curcumin</z:chebi> and <z:chebi fb="1" ids="50694">minocycline</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>Uncovering underlying mechanisms contributing to the success of <z:hpo ids='HP_0011009'>acute</z:hpo> therapy in <z:mp ids='MP_0002055'>diabetes</z:mp> will advance tailored <z:hpo ids='HP_0001297'>stroke</z:hpo> therapies </plain></SENT>
</text></document>